SLC5A2 and Hypoglycemia: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors are two new antidiabetic drugs that show promise for improving glycemic control while posing less risk for hypoglycemia [37,38].